Discontinued — last reported Q4 '16
Short-Term Investments
Royalty Pharma Short-Term Investments increased by 16.5% to $21.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 81.0%, from $12.10M to $21.90M. Over 5 years (FY 2020 to FY 2025), Short-Term Investments shows a downward trend with a -23.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests the company is effectively deploying excess cash to earn returns; a decrease may indicate cash usage for operations or acquisitions.
Detailed definition
These are marketable securities and other financial instruments that the company intends to hold for more than three mon...
Peer comparison
Common for companies with significant cash reserves and active treasury management.
short_term_investmentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $68.70M | $67.02M | $66.00M | $64.80M | $363.70M | $409.35M | $1.30M | $2.50M | $5.10M | $5.30M | $18.30M | $29.00M | $38.50M | $48.50M | $58.20M | $12.10M | $13.20M | $16.10M | $18.80M | $21.90M |
| QoQ Change | — | -2.5% | -1.5% | -1.8% | +461.3% | +12.6% | -99.7% | +92.3% | +104.0% | +3.9% | +245.3% | +58.5% | +32.8% | +26.0% | +20.0% | -79.2% | +9.1% | +22.0% | +16.8% | +16.5% |
| YoY Change | — | — | — | — | +429.4% | +510.8% | -98.0% | -96.1% | -98.6% | -98.7% | >999% | >999% | +654.9% | +815.1% | +218.0% | -58.3% | -65.7% | -66.8% | -67.7% | +81.0% |
Short-Term Investments at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's short-term investments?
- Royalty Pharma (RPRX) reported short-term investments of $21.90M in Q1 2026.
- How has Royalty Pharma's short-term investments changed year-over-year?
- Royalty Pharma's short-term investments increased by 81.0% year-over-year, from $12.10M to $21.90M.
- What is the long-term trend for Royalty Pharma's short-term investments?
- Over 5 years (2020 to 2025), Royalty Pharma's short-term investments has grown at a -23.1% compound annual growth rate (CAGR), from $69.98M to $18.80M.
- What does short-term investments mean?
- Liquid investments maturing between three months and one year.